If any one of these predictions demonstrated significant benefit, it would represent the first standard-of-care molecular biomarker selection for MYCN non-amplified neuroblastomas and a foundational step toward personalised therapy for this devastating disease. The gene discussed is MYCN; the disease is neuroblastoma.